Phorbol 12-myristate 13-acetate (PMA)

Catalog No.S7791 Synonyms: 12-O-Tetradecanoylphorbol-13-acetate,TPA, Phorbol myristate acetate

For research use only.

Phorbol 12-myristate 13-acetate (PMA,12-O-Tetradecanoylphorbol-13-acetate, TPA, Phorbol myristate acetate), a potent activator of PKC, is active at nanomolar concentrations. Phorbol 12-myristate 13-acetate (PMA) induces sphingosine-1-phosphate (S1P).

Phorbol 12-myristate 13-acetate (PMA) Chemical Structure

CAS No. 16561-29-8

Selleck's Phorbol 12-myristate 13-acetate (PMA) has been cited by 28 publications

Purity & Quality Control

Choose Selective PKC Inhibitors

Other PKC Products

Biological Activity

Description Phorbol 12-myristate 13-acetate (PMA,12-O-Tetradecanoylphorbol-13-acetate, TPA, Phorbol myristate acetate), a potent activator of PKC, is active at nanomolar concentrations. Phorbol 12-myristate 13-acetate (PMA) induces sphingosine-1-phosphate (S1P).
In vitro

In endothelial cells, PMA increases levels of Thy-1 mRNA and protein, induces Thy-1 up-regulation and inhibits capillary-like tube formation and endothelial cell migration.[1]

Assay
Methods Test Index PMID
Western blot pERK / ERK1 / pp38 / p38 ; p-GSK3β / GSK3β / Lamin B2 22977714 27405982
Immunofluorescence cTnT / β-MHC / CD90 27405982
In vivo

In the zebrafish model, PMA initially enhances endothelial cell migration, subsequently activates the PKC-δ/Syk/NF-κB-mediated pathway to up-regulate Thy-1, which in turn inhibits endothelial cell migration.[1]

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: Human umbilical vein endothelial cells (HUVECs), human dermal microvascular endothelial cells (HDMECs), human pulmonary microvascular endothelial cell line (HPMECs)
  • Concentrations: 20 ng/mL
  • Incubation Time: 14, 16 and 18 h for levels of Ty-1 mRNA, 20, 24 and 28 h for levels of Ty-1 protein
  • Method:

    After transfection with Ty-1 promoter plasmid (0.5 μg) and Renilla plasmid (50ng), the cells are treated with PMA (20ng/mL), and washed with ice-cold phosphate-buffered saline (PBS), and then lysed in passive lysis buffer. Luciferase activity is measured using the Dual-Luciferase Reporter Assay kit.

Animal Research:

[1]

  • Animal Models: Transgenic Tg(fi1:EGFP)y1 embryos of zebrafsh (Danio rerio)
  • Dosages: 20 ng/mL
  • Administration: --

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 616.83
Formula

C36H56O8

CAS No. 16561-29-8
Storage 3 years -20°C(in the dark) powder
2 years -80°C(in the dark) in solvent
Smiles CCCCCCCCCCCCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)C)O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05446272 Not yet recruiting Device: NIV-NAVA|Device: NS-NIPPV Extubation Failure|Bronchopulmonary Dysplasia|Death University of Pennsylvania|National Heart Lung and Blood Institute (NHLBI) August 1 2022 Not Applicable
NCT05416151 Recruiting Other: Freeze-dried biotic|Other: Maltodextrin Gastro-intestinal Symptoms in Healthy Subjects Danone Research|Euraxi Pharma May 24 2022 Not Applicable
NCT05443243 Completed Procedure: Total Hip Arthroplasty Hip Arthritis University Hospital Brest May 13 2022 --
NCT04986839 Recruiting Drug: Paracetamol injection|Drug: Ibuprofen injection Patent Ductus Arteriosus Manchester University NHS Foundation Trust September 3 2021 Phase 2|Phase 3
NCT04251377 Recruiting Device: Defensive Antiadhesive Coating DAC® Novagenit SRL Hip Prosthesis Infection Centre Hospitalier Universitaire de Saint Etienne|Ministry of Health France September 30 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Phorbol 12-myristate 13-acetate (PMA) | Phorbol 12-myristate 13-acetate (PMA) supplier | purchase Phorbol 12-myristate 13-acetate (PMA) | Phorbol 12-myristate 13-acetate (PMA) cost | Phorbol 12-myristate 13-acetate (PMA) manufacturer | order Phorbol 12-myristate 13-acetate (PMA) | Phorbol 12-myristate 13-acetate (PMA) distributor